attorneys « New Search
« Back
Photo of Jane S. Berman

Jane S. Berman

JANE BERMAN is a member of Taft’s Pharmaceutical & Life Sciences Litigation practice group, concentrating her practice in patent prosecution and Hatch-Waxman ANDA litigation matters. 

Patent Litigation

Jane’s work has included litigation to help bring to market generic versions of a number of brand name drugs.  Her work has included Hatch-Waxman opinion work and litigation in federal court and U.S.  Patent Trial and Appeal Board (PTAB) matters concerning drugs such as ANGIOMAX (bivalirudin), DALIRESP (roflumilast), FANAPT (iloperidone), JEVTANA KIT (cabazitaxel), KYPROLIS (carfilzomib), LASTACAFT (alcaftadine), LEXIVA (fosamprenavir calcium), SAMSCA (tolvaptan), TEFLARO (ceftaroline fosamil), and XARELTO (rivaroxaban).  She has represented parties in inter partes reviews instituted by the PTAB in fields including pharmaceuticals and telecommunications.  Jane co-authored a chapter in the second edition of ANDA Litigation: Strategies & Tactics for Pharmaceutical Patent Litigators published in 2016. 

IP Counseling and Prosecution 

Jane has many years’ experience in prosecuting protections for all types of intellectual property, including patents, trade secrets, trademarks and copyrights. Jane manages international patent and trademark portfolios and is experienced in using the Patent Cooperation Treaty, Madrid Protocol and other international legal tools to obtain patents and trademark registrations for her clients in the U.S. and abroad. Her broad international prosecution experience includes obtaining dozens of patents on improved medical devices, thermoplastic compositions, optical modulators and other optoelectronic devices, mining equipment, smelting furnaces, calcination and smelting processes, and internal combustion engines.

IP Transactional Experience

Jane’s extensive work at banking firms has honed her abilities in advising on the intellectual property aspects of complex corporate and financial transactions, including many significant corporate acquisitions and licensing transactions.  She has years of experience in advising major international banking institutions on the IP aspects of commercial lending transactions. She frequently provides opinions on strength of patent portfolios that affect decisions on private equity, lending, and restructuring deals.